<DOC>
	<DOCNO>NCT00543569</DOCNO>
	<brief_summary>A study ass safety efficacy Alefacept de novo kidney transplant patient .</brief_summary>
	<brief_title>A Study Assess Safety Efficacy Alefacept Kidney Transplant Recipients</brief_title>
	<detailed_description>This 4 arm ( active ) study determine safety efficacy Alefacept de novo kidney transplant recipient .</detailed_description>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Basiliximab</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Alefacept</mesh_term>
	<criteria>Subject anticipate receive first oral dose tacrolimus within 48 hour transplant procedure Subject recipient de novo kidney transplant Subject recipient kidney nonhuman leukocyte antigen ( HLA ) identical related living donor , nonrelated living donor , decease donor Subject screening ( preoperative ) estimate cluster differentiation ( CD ) 4+ Tcell count &lt; 250 cells/ÂµL Subject receive kidney anticipate cold ischemia time ( CIT ) &gt; 30 hour Recipient positive T Bcell cross match investigational site 's standard method determination Subject receive kidney 5065 year old decease donor one following : History hypertension terminal serum creatinine &gt; 1.5 mg/dL Cerebrovascular accident cause death terminal serum creatinine &gt; 1.5 mg/dL History hypertension cerebrovascular accident cause death terminal serum creatinine &gt; 1.5 mg/dL</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>kidney transplant</keyword>
	<keyword>alefacept</keyword>
</DOC>